These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2934257)

  • 1. Adrenal androgen blockade in relapsed prostate cancer.
    Geller J; Albert JD
    Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1127-31. PubMed ID: 2934257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
    Geller J
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of prostatic cancer. Newer forms of androgen deprivation.
    Soloway MS
    Postgrad Med; 1986 Jul; 80(1):249-52, 257-8. PubMed ID: 2941729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
    Geller J; Albert J; Vik A
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).
    Geller J; Albert J
    Urol Res; 1987; 15(3):151-3. PubMed ID: 3629749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced prostatic cancer.
    Sogani PC; Fair WR
    Urol Clin North Am; 1987 May; 14(2):353-71. PubMed ID: 2953100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
    Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
    J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basis for hormonal management of advanced prostate cancer.
    Geller J
    Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The endocrine profile in prostatic cancer: therapeutic implications].
    Calvo Mateo MA; Castellanos Llorens JM; Galán Ortega A
    Actas Urol Esp; 1981; 5(1):3-12. PubMed ID: 7015803
    [No Abstract]   [Full Text] [Related]  

  • 14. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
    Labrie F; Dupont A; Bélanger A; Cusan L; Giguère M; Lacourcière Y; Luthy I; Bégin D; Labrie C; Simard J
    Cancer Metastasis Rev; 1987; 6(4):615-36. PubMed ID: 3327635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapy: where do we stand and where are we going?
    Schröder FH
    Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats.
    el Etreby MF; Habenicht UF; Louton T; Nishino Y; Schröder HG
    Prostate; 1987; 11(4):361-75. PubMed ID: 2960960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
    Labrie C; Cusan L; Plante M; Lapointe S; Labrie F
    J Steroid Biochem; 1987 Oct; 28(4):379-84. PubMed ID: 2444770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined androgen blockade in advanced prostate cancer: looking back to move forward.
    Chodak G; Gomella L; Phung de H
    Clin Genitourin Cancer; 2007 Sep; 5(6):371-8. PubMed ID: 17956709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.